Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.3.1.107 (
DAT
)
1,471
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Drugs that inhibit the dopamine (DA) transporter (
DAT
) include both therapeutic agents and abused drugs. Recent studies identified a novel series of putative allosteric
DAT
inhibitors, but the in vivo effects of these compounds are unknown. This study examined the abuse-related behavioral and neurochemical effects produced in rats by
SRI
-31142 [2-(7-methylimidazo[1,2-a]pyridin-6-yl)-N-(2-phenyl-2-(pyridin-4-yl)ethyl)quinazolin-4-amine], one compound from this series. In behavioral studies, intracranial self-stimulation (ICSS) was used to compare the effects produced by
SRI
-31142, the abused and nonselective
DAT
inhibitor cocaine, and the selective
DAT
inhibitor GBR-12935 [1-[2-(diphenylmethoxy)ethyl]-4-(3-phenylpropyl)piperazine]. In neurochemical studies, in vivo microdialysis was used to compare the effects of
SRI
-31142 and cocaine on levels of DA and serotonin in nucleus accumbens (NAc). The effects of
SRI
-31142 in combination with cocaine were also examined in both procedures. In contrast to cocaine and GBR-12935,
SRI
-31142 failed to produce abuse-related increases in ICSS or NAc DA; instead,
SRI
-31142 only decreased ICSS and NAc DA at a dose that was also sufficient to block cocaine-induced increases in ICSS and NAc DA. Pharmacokinetic studies suggested low but adequate brain penetration of
SRI
-31142, in vitro binding studies failed to identify likely non-
DAT
targets, and in vitro functional assays failed to confirm DA uptake inhibition in an assay of
DAT
-mediated fluorescent signals in live cells. These results indicate that
SRI
-31142 does not produce cocaine-like abuse-related effects in rats.
SRI
-31142 may have utility to block cocaine effects and may warrant further study as a candidate pharmacotherapy; however, the role of
DAT
in mediating these effects is unclear, and side effects may be a limiting factor.
...
PMID:Interactions between Cocaine and the Putative Allosteric Dopamine Transporter Ligand SRI-31142. 3015 Apr 82